Antibody–Bottlebrush Conjugates for Targeted Cancer Therapy

Abstract: Antibody–drug conjugates (ADCs) are powerful targeted therapies but are limited by narrow payload diversity and chemical constraints. In this talk, I will introduce antibody–bottlebrush prodrug conjugates (ABCs) that overcome these barriers. ABCs feature antibodies covalently linked to polymeric bottlebrush prodrugs carrying diverse, tunable payloads at ultra-high drug-to-antibody ratios without compromising antibody function. This design enables precise tumor targeting, superior efficacy, and minimal toxicity in preclinical models, offering a promising next-generation therapeutic strategy.